BioSpace News Archive

MaaT Pharma announced that the first patient has been dosed in its pivotal Phase 3 trial investigating MaaT013 in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement who are refractory to both steroids, the standard of care first-line treatment, and to ruxolitinib1 used as a second-line treatment.

The industry analysis report is considered a valuable source of information about the global Serotonin Antagonists industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The global acute hospital care market size is expected to worth around US$ 4.58 Trillion by 2027 and expanding growth at a CAGR 6.5% over the forecast period 2021 to 2027.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

According to Precedence Research, the global drug discovery market size is projected to hit US$ 161.76 billion by 2030 and is growing at a noteworthy CAGR of 8.9% from 2021 to 2030.

The medical oxygen concentrator’s market growth is estimated to reach at a CAGR of 12.8% during the forecast period and to reach valuation US$ 4.99 billion by 2030.

Chandra Ramanathan, executive-in-residence at Mass General Brigham and a biopharmaceutical executive with extensive experience translating scientific ideas into treatment options and access for patients with high medical needs, has joined McLean Hospital’s Board of Trustees.

Progenity, Inc., an innovative biotechnology company, provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2021.

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE’s board of directors.

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced financial results for the full year ended December 31, 2021.